Rs 450 to Rs 4,200: Drugmakers rush in to win the business of losing weight India’s obesity drug market is experiencing rapid expansion as pharmaceutical companies compete to capture a growing segment of the healthcare industry. With rising obesity rates and diabetes prevalence, drugmakers are adjusting pricing strategies and launching generic alternatives to meet demand. Analysts predict the market could grow from approximately Rs 1,500 crore today to Rs 8,000 crore by 2030, driven by both brand-name and generic drugmakers entering the space. Novo Nordisk, a leading player in the weight-loss drug market, recently reduced the price of its Wegovy in India by up to 37%, pricing the lowest dose at Rs 10,850 per month. It also introduced Ozempic at Rs 8,800 per month for the 0.25 mg dose. These price cuts have made the drugs more accessible, but experts warn that the influx of generic options could lead to confusion among prescribers and potential misuse. Over 40 Indian pharmaceutical companies are expected to launch more than 50 brands within weeks, according to Reuters. This surge in competition is aimed at addressing the needs of a population projected to have over 440 million overweight or obese adults by 2050. India, the world’s most populous nation, already has the second-highest number of adults with diabetes after China, according to The Lancet and the International Diabetes Federation. The pricing of weight-loss drugs in India varies significantly, with some generics available for as low as Rs 450 per week. A table detailing the prices of major drugs shows: Alkem Labs offers an injection at Rs 450 weekly or Rs 1,800 monthly. Sun Pharma’s injection ranges from Rs 750–900 weekly. Dr. Reddy’s provides the highest monthly price at Rs 4,200 for its injection.#novonordisk #ozempic #wegovy #sun_pharma #alkem_labs
